DUBLIN – Zealand Pharma A/S has attained the most significant milestone in its 18-year history, the FDA approval of Sanofi SA's type 2 diabetes combo product, Soliqua 100/33 (insulin glargine and lixisenatide injection, or Lixilan), which adds Zealand's glucagon-like peptide receptor agonist Adlyxin (lixisenatide) to the big pharma firm's basal insulin in a fixed-dose pen.